Assessment of Median and Mean Survival Time in Cancer Clinical Trials

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2023 Apr 3

PMID 37010873

Authors

Ananya Das

Timothy A Lin

Christine Lin

Tomer Meirson

Zachary R McCaw

Lu Tian

Ethan B Ludmir

Affiliations

Soon will be listed here.

Citing Articles

Descriptive statistics for cardiothoracic surgeons: part 2 - the foundation of data interpretation.

Ahmed H Indian J Thorac Cardiovasc Surg. 2024; 41(1):89-110.

PMID: 39679094 PMC: 11638441. DOI: 10.1007/s12055-024-01855-x.

Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.

Liao Y, Zhou Y, Zhou X, Chen J, Chen Z, Liao J PLoS One. 2024; 19(11):e0311758.

PMID: 39527539 PMC: 11554179. DOI: 10.1371/journal.pone.0311758.

Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.

Lin T, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R Clin Cancer Res. 2024; 30(20):4791-4799.

PMID: 39133081 PMC: 11479825. DOI: 10.1158/1078-0432.CCR-24-0566.

Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.

Sherry A, Msaouel P, Kouzy R, Abi Jaoude J, Lin T, Taniguchi C Oncologist. 2024; 29(7):547-550.

PMID: 38824414 PMC: 11224967. DOI: 10.1093/oncolo/oyae067.

Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.

Shao Y, Kay N, Gale R, Liang Y Leukemia. 2024; 38(7):1469-1473.

PMID: 38824147 DOI: 10.1038/s41375-024-02294-8.

References

Ben-Aharon O, Magnezi R, Leshno M, Goldstein D . Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist. 2019; 24(11):1469-1478. PMC: 6853128. DOI: 10.1634/theoncologist.2019-0175. View

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

McCaw Z, Kim D, Wei L . Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations. JNCI Cancer Spectr. 2022; 6(1). PMC: 8877166. DOI: 10.1093/jncics/pkac007. View

Patel R, Verma V, Fuller C, McCaw Z, Ludmir E . Transparency in reporting of phase 3 cancer clinical trial results. Acta Oncol. 2020; 60(2):191-194. PMC: 7951952. DOI: 10.1080/0284186X.2020.1856410. View

Pak K, Uno H, Kim D, Tian L, Kane R, Takeuchi M . Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncol. 2017; 3(12):1692-1696. PMC: 5824272. DOI: 10.1001/jamaoncol.2017.2797. View